证券研究报告 | 首次覆盖报告 gszqdatemark 2025 11 24 年 月 日 万辰集团（300972.SZ） 复盘来时路，展望启新章 复盘发展历程：食用菌龙头，转型走出量贩高成长之路。万辰自 2011 年 成立后深耕食用菌领域，2020 年即成为农业产业化国家重点龙头企业， 2024 年食用菌实现 5.4 亿元营收。2022 年切入量贩零食赛道，前期以收 购模式快速形成门店布局网络，同步进行物流仓储等基础体系建设，2023 年后集中资源自行扩店，至 2025 年 6 月末达成 15365 家门店，并不断探 索多品类新店型，2025 年前三季度量贩营收 361.6 亿元，同比+78.8%， 占比提升至 98.9%，同时规模效应牵引 25Q3 量贩单季度净利率提升至 5.3%，同比大幅提升 2.6pct。 复盘股权结构：子公司结构落成，扩店与激励共同推进。万辰实控人王泽 宁先生持股 34.4%，主导量贩零食业务的收购及拓展，万辰的并购之路沿 着" 设立控股子公司-向子公司提供财务支持-推动股权激励-收回少数股东 权益"的路径演进。2022-2023 年公司陆续收购零食工坊、陆小馋，与好 想来、来优品 ...

11月21日，华绿生物跌4.84%，成交额6828.70万元。两融数据显示，当日华绿生物获融资买入额589.58 万元，融资偿还598.55万元，融资净买入-8.97万元。截至11月21日，华绿生物融资融券余额合计 4625.30万元。 融资方面，华绿生物当日融资买入589.58万元。当前融资余额4625.30万元，占流通市值的2.25%，融资 余额低于近一年50%分位水平，处于较低位。 融券方面，华绿生物11月21日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，江苏华绿生物科技集团股份有限公司位于江苏省泗阳县绿都大道88号，成立日期2010年6月8 日，上市日期2021年4月12日，公司主营业务涉及食用菌的研发、工厂化种植及销售。主营业务收入构 成为：金针菇70.73%，真姬菇29.27%。 截至9月30日，华绿生物股东户数1.03万，较上期减少9.42%；人均流通股9132股，较上期增加11.88%。 2025年1月-9月，华绿生物实现营业收入8.68亿元，同比增长17.98%；归母净 ...

Core Viewpoint - The company, Hualv Biotechnology, has reported a significant increase in revenue projections for 2024, reaching 1.032 billion yuan, up from 578 million yuan in 2021, indicating strong growth in its product offerings and market expansion [1] Product Offerings - The main products of the company include enoki mushrooms, true shiitake mushrooms (which encompass varieties such as crab-flavored and white jade mushrooms), maitake mushrooms, cordyceps flowers, and deer antler mushrooms [1] - Cordyceps flowers and deer antler mushrooms are newly launched products post-IPO, showcasing the company's commitment to diversifying its product range [1] Revenue Growth - The projected revenue for 2024 is 1.032 billion yuan, which represents a notable increase compared to the 578 million yuan reported in 2021, highlighting the company's growth trajectory [1]

Core Viewpoint - The company, Hualv Biotechnology, has reported significant growth in its product offerings and revenue, projecting a revenue of 1.032 billion yuan in 2024, which represents a substantial increase from 578 million yuan in 2021, indicating a doubling of both production capacity and revenue [1]. Group 1: Product Diversification - The main products of the company include enoki mushrooms, king oyster mushrooms (including crab-flavored and white jade varieties), maitake mushrooms, cordyceps flowers, and deer antler mushrooms, with the latter two being introduced after the company's IPO [1]. - The company has achieved industrialized production of edible mushroom products under its diversified layout, with ongoing inquiries about new specialty varieties [3]. Group 2: Capacity and Revenue Growth - The company anticipates that its revenue for 2024 will reach 1.032 billion yuan, which is a notable increase from 578 million yuan in 2021, reflecting a clear growth trajectory [1]. - The company has successfully doubled its production capacity and revenue since its listing, with specific inquiries regarding the new and expanded production bases planned for 2024 and 2025 [3].

Core Viewpoint - Huagu Bio (300970) is focusing on its main products, enoki mushrooms and king oyster mushrooms, which benefit from agricultural tax incentives [1] Company Summary - The company's subsidiary in Guangxi primarily produces enoki mushrooms and king oyster mushrooms [1] - The company is continuously monitoring the synthetic biology field but has not yet initiated research and development in this area [1]

Group 1 - The core viewpoint of the news is that Xue Rong Biological has experienced a decline in stock price despite a significant increase in its stock value year-to-date, indicating potential volatility in the market [1][2] - As of October 14, Xue Rong Biological's stock price was 6.58 CNY per share, with a market capitalization of 4.126 billion CNY and a trading volume of 236 million CNY [1] - The company has seen a year-to-date stock price increase of 89.63%, with a 9.30% increase over the last five trading days [1] Group 2 - Xue Rong Biological operates in the agricultural sector, specifically in the cultivation and sale of edible mushrooms, with a revenue composition of 73.31% from enoki mushrooms and 22.27% from king oyster mushrooms [1][2] - As of June 30, the number of shareholders decreased by 14.57% to 30,200, while the average circulating shares per person increased by 28.64% to 17,119 shares [2] - For the first half of 2025, the company reported a revenue of 791 million CNY, a year-on-year decrease of 26.17%, and a net profit loss of 103 million CNY, which represents a year-on-year increase of 28.58% [2] Group 3 - Since its A-share listing, Xue Rong Biological has distributed a total of 236 million CNY in dividends, with no dividends paid in the last three years [3]

Company Overview - Shanghai Xuerong Biotechnology Co., Ltd. is located at 1487 Huifeng West Road, Fengxian District, Shanghai, established on December 8, 1997, and listed on May 4, 2016 [1] - The company's main business involves the research and development, cultivation, and sales of edible mushrooms, with revenue composition as follows: Enoki mushrooms 73.31%, King oyster mushrooms 22.27%, others 1.65%, supplementary 1.58%, and culture medium 1.19% [1] Stock Performance - On September 25, Xuerong Biotechnology's stock rose by 2.18%, reaching 6.08 CNY per share, with a trading volume of 84.26 million CNY and a turnover rate of 2.75%, resulting in a total market capitalization of 3.634 billion CNY [1] - Year-to-date, the stock price has increased by 75.22%, with a 3.93% rise over the last five trading days, a 3.65% decline over the last 20 days, and an 8.02% decline over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on May 20, where it recorded a net purchase of 57.18 million CNY [1] Financial Performance - For the first half of 2025, Xuerong Biotechnology reported operating revenue of 791 million CNY, a year-on-year decrease of 26.17%, and a net profit attributable to the parent company of -103 million CNY, a year-on-year increase of 28.58% [2] - The company has distributed a total of 236 million CNY in dividends since its A-share listing, with no dividends distributed in the last three years [3] Shareholder Information - As of June 30, the number of shareholders for Xuerong Biotechnology was 30,200, a decrease of 14.57% from the previous period, while the average circulating shares per person increased by 28.64% to 17,119 shares [2] Industry Classification - Xuerong Biotechnology belongs to the agricultural, forestry, animal husbandry, and fishery sector, specifically in the planting industry focused on edible mushrooms [2] - The company is associated with several concept sectors, including NMN concept, small-cap, low-price, biopharmaceuticals, and rural revitalization [2]

Core Viewpoint - Fujian Wancheng Biotechnology Group Co., Ltd. (Wancheng Group) has submitted its prospectus for listing on the Hong Kong Stock Exchange, aiming to expand its operations and enhance its market presence [1][9]. Group 1: Company Overview - Wancheng Group is the parent company of the snack brand "Haoxianglai" and was listed on the Shenzhen Stock Exchange in April 2021 with an IPO price of 7.19 CNY per share, raising approximately 276 million CNY [3][9]. - The company focuses on the research, cultivation, and sales of fresh edible fungi, and has recently expanded into the retail snack industry [7][9]. Group 2: Financial Performance - Wancheng Group's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately 549 million CNY, 9.29 billion CNY, 32.33 billion CNY, and 10.92 billion CNY, respectively [13][14]. - The net profit figures for the same periods were approximately 67.85 million CNY, -176.21 million CNY, 610.91 million CNY, and 136.17 million CNY [14][16]. Group 3: Investment Projects - The company initially planned to raise 600 million CNY for various projects, including a 21,000-ton mushroom production facility, but later adjusted its fundraising goals and project allocations [4][5][10]. - In September 2023, Wancheng Group announced a reduction in the investment amount for the "60-ton daily mushroom production project" from approximately 130 million CNY to 80.6 million CNY, reallocating the remaining funds to the "53,000-ton golden needle mushroom production project" [5][6]. Group 4: Shareholder Structure - As of December 31, 2022, the actual controller of Wancheng Group, Wang Zenin, held a direct stake of 5.08% and controlled a total of 51.26% of the company through various entities [7][9]. - Wang Zenin participated in a private placement of shares at a price of 11.30 CNY per share, raising 200 million CNY for brand marketing and operational support projects [10][12]. Group 5: Market Position and Future Plans - Wancheng Group's brand "Haoxianglai" is projected to rank first in China's snack and beverage retail sector by GMV in 2024, with over 15,000 stores across 29 provinces and municipalities by June 30, 2025 [12][13]. - The company has integrated its snack brands into a national brand strategy, enhancing its market presence and operational efficiency [8][9].

Company Overview - Jiangsu Hualv Biotechnology Group Co., Ltd. is located at 88 Lvdou Avenue, Siyang County, Jiangsu Province, established on June 8, 2010, and listed on April 12, 2021 [1] - The company's main business involves the research, industrial cultivation, and sales of edible mushrooms, with revenue composition being 70.73% from enoki mushrooms and 29.27% from king oyster mushrooms [1] Stock Performance - As of September 23, the stock price of Hualv Biotechnology decreased by 2.07%, trading at 13.70 CNY per share, with a total market capitalization of 1.664 billion CNY [1] - Year-to-date, the stock price has increased by 15.13%, but it has seen declines of 6.87% over the last five trading days, 12.07% over the last 20 days, and 8.30% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on April 8 [1] Financial Performance - For the first half of 2025, Hualv Biotechnology reported a revenue of 499 million CNY, representing a year-on-year growth of 7.78%, while the net profit attributable to shareholders was -53.6947 million CNY, a decrease of 19.79% year-on-year [1] - Cumulative cash dividends since the A-share listing amount to 76.7904 million CNY, with 46.4484 million CNY distributed over the past three years [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 11.49% to 11,400, with an average of 8,162 circulating shares per person, a decrease of 10.31% [1] - Among the top ten circulating shareholders, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A ranks as the third-largest shareholder, holding 2.0213 million shares, an increase of 1.2423 million shares from the previous period [2]

Core Viewpoint - The report details the usage of previously raised funds by Fujian Wancheng Biotechnology Group Co., Ltd., highlighting the financial management and adjustments made to investment projects to enhance operational efficiency and market competitiveness [2][12][14]. Fundraising Overview - The company raised a net amount of RMB 228.60 million from its initial public offering (IPO) after deducting issuance costs [2]. - In a subsequent issuance to specific investors, the company raised RMB 200 million, with a net amount of RMB 193.60 million after expenses [3]. Fund Usage and Management - As of June 30, 2025, the company had utilized RMB 162.59 million from the IPO funds and RMB 142.49 million from the specific issuance funds [4][5]. - The company established special accounts for managing the raised funds, ensuring compliance with regulatory requirements and protecting investor interests [9][10]. Project Adjustments - The company changed the investment project from "Annual Production of 21,000 Tons of Shimeji Mushroom" to "Annual Production of 53,000 Tons of Enoki Mushroom," aiming to improve market competitiveness and reduce production costs [12][14]. - The adjusted investment amount for the new project is RMB 100 million, with a total planned investment of RMB 470.57 million [14]. Financial Performance - As of June 30, 2025, the project for producing 53,000 tons of Enoki mushrooms reported a cumulative loss of RMB 51.39 million, indicating challenges in the edible mushroom business due to market conditions [16].